Olive Garden Raises $2 Million for Leukemia Society

Publication
Article
OncologyONCOLOGY Vol 11 No 11
Volume 11
Issue 11

Olive Garden Italian Restaurants recently reached their goal of raising $2 million through its “Pasta for Pennies” program to

Olive Garden Italian Restaurants recently reached their goal of raising $2 million through its “Pasta for Pennies” program to benefit the Leukemia Society of America. The program encourages elementary, middle, and high school students around the country to donate any spare change they can find. The class that raises the most money receives a pasta lunch from the restaurant chain.

More than 1,500 schools nationwide recently contributed their spare change to help Olive Garden reach this year’s goal. “We salute students, teachers, and parents for their participation in “Pasta for Pennies,” said Brad Blum, President of the Olive Garden Italian Restaurant.

More than 290 Olive Garden Restaurants participated in “Pasta for Pennies” this year. In addition to a pasta lunch, schools have the chance to win such prizes as computers, televisions, and educational trips. Olive Garden further supports the program by hosting kick-off luncheons for participating schools and providing market support.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content